Menu
  • Join
  • Login
  • Contact
 

Search abstracts / presentations


Development of PEGylated aspartic acid modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis

  • In: Poster Presentation
  • At: Stockholm (Sweden) (2017)
  • Type: Poster
  • Poster code: P-B-117-Tuesday
  • By: YAMASHITA, Shugo (Kyoto Pharmaceutical University, Biopharmaceutics, Kyoto, Japan)
  • Co-author(s): Shugo Yamashita: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Hidemasa Katsumi: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Nozomi Hibino: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Yugo Isobe: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Yumiko Yagi: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Yuka Tanaka: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Saki Yamada: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Kosuke Kusamori: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Toshiyasu Sakane: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
    Akira Yamamoto: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
  • Abstract:

    Backgrounds

    The number of bone metastasis patients has been rapidly increasing in association with the global population aging. However, most anticancer drugs do not have a high affinity for bone hydroxyapatite under physiological conditions. Therefore, development of bone targeting system is highly required for the treatment of bone metastasis. In ..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses